No Data
No Data
No Data
No Data
No Data
興科蓉醫藥:年報 2023
Futu NewsApr 22 06:09 ET · Announcements
Xingkerong Pharmaceutical (6833.HK): Revenue increased 11.8% year over year, ready to go
In 2023, in an environment where external uncertainties still exist, the Hong Kong stock pharmaceutical market experienced significant fluctuations, and the sector is still below the historical valuation center. However, there are still excellent companies in the pharmaceutical sector that have shown good ability to cross the cycle, and have performed well with high performance flexibility and stable fundamentals, such as Xingkerong Pharmaceutical, a leading marketing, promotion and channel management service provider in the domestic pharmaceutical industry. Recently, Xingkerong Pharmaceutical announced its 2023 annual results. According to the results announcement, the company's revenue achieved a steady increase of 11.8%, reaching RMB 2.54 billion. This one percent
Gelonghui FinanceApr 1 20:32 ET
Sinco Pharmaceuticals' 2023 Profit Declines on Higher Tax Payments
Sinco Pharmaceuticals Holdings' (HKG:6833) attributable profit declined to 42.4 million yuan, or 0.021 yuan per share, in 2023, from 69.5 million yuan, or 0.034 yuan per share, in 2022, according to a
MT NewswiresMar 26 23:53 ET
Xingkerong Pharmaceutical (06833) Announces 2023 Annual Results, Excellent Core Product Results, Dual Track Layout Continues to Deepen and Advance
The Zhitong Finance App learned that on the evening of March 26, Xingkerong Pharmaceutical (06833) announced its 2023 annual results, with revenue growth of 11.8% to RMB 2,540.1 million. Among them, sales revenue of human albumin injections increased by about RMB 249.8 million, and revenue from the medical and aesthetic business increased by RMB 13.7 million. During the reporting period, the company's gross profit increased by RMB 17.4 million to RMB 323.3 million. The increase in gross profit was mainly due to increased revenue from human albumin sales and medical and aesthetic services. At the same time, in order to return long-term shareholders' support, the company's board of directors recommended declaring a final dividend per share
Zhitong FinanceMar 26 21:57 ET
Xingkerong Pharmaceutical (06833.HK) revenue increased 11.8% to 2.54 billion yuan in 2023
Gelonghui, March 26, 丨 Xingkerong Pharmaceutical (06833.HK) announced that in its annual results for the year ended December 31, 2023, the Group's revenue increased 11.8% to RMB 2.54 billion. Among them, sales revenue of human albumin injections increased by about RMB 250 million, mainly due to the increase in sales volume. During the reporting period, net profit attributable to company owners was RMB 42.4 million; basic and apportioned profit per share was RMB 0.02 (2022: basic and diluted earnings per share of RMB 0.03). Board resolution for the year ended 31 December 2023
Gelonghui FinanceMar 26 11:36 ET
Xingkerong Pharmaceutical (06833) announced annual results. Profit attributable to shareholders of RMB 42.352 million decreased by 39.03% year-on-year, with final interest of HK0.39 cents per share
Xingkerong Pharmaceutical (06833) announced the results for the year ended December 31, 2023. The group's beneficiaries...
Zhitong FinanceMar 26 11:05 ET
No Data
No Data